European Biotechnology Congress 2017 will be held under auspices of the President of the Republic of Croatia, Madam Kolinda Grabar-Kitarović.
Confirmed Speakers - Eurobiotech Congress 2017

Confirmed Speakers

BIO SKETCH - MARK JC NUIJTEN PhD, MD, MBA
(http://a2m.nl/)

Dr. Mark Nuijten trained as a physician and worked in clinical practice before obtaining an international M.B.A. from Erasmus University, Rotterdam, with a focus on financial management. He obtained his PhD in health economics (2003) on the thesis “In search of more confidence in health economic modelling” at the Erasmus University, Rotterdam. Dr. Nuijten has become one of the top health economic experts over the last decade, reflected in more than 180 publications and leading positions in scientific societies and editorial boards. Dr. Nuijten was Board Director of ISPOR (2002-2004) and Chair of the Management Board of Value in Health (2002-2004). He was member of the Editorial Advisory Board of Value in Health. Dr. Nuijten is internationally renowned for achievements in mathematical modelling, also reflected in many publications and positive reimbursement decisions in many markets for innovative medications by institutions, like NICE in England.
He is a pioneer in the field of healthcare innovation in biotechnology and nutrition, and has been the first classical health economist successfully applying and developing sales forecast methodologies for valuation of biotechnology companies. For example, developing a Pricing Matrix Model for research in early phase development and a Financial Valuation Algorithm for the assessment of the future sales of a new, innovative medicinal product.
Dr Nuijten is pursuing development of economic modelling and broadening its application in health care and finance. His models successfully contributed to positive reimbursement decisions by health authorities in many countries, (for example, SMC in Scotland, TLV in Sweden, and The National Health Care Institute in The Netherlands).
He is academic supervisor of PhD programs at the Universities of Maastricht and Groningen in The Netherlands and founder of the ISPOR Special Interest Group on nutrition-economics.

Dr. Nuijten owns and runs A2M (Ars Accessus Medica - http://a2m.nl/), which provides international consulting services in health economics, pricing, market access and valuation in biotechnology. A2M is a partner of Minerva, an international health economics consortium. A2M established other global collaborations with key opinion formers in key European markets, the US, Canada and Japan. A2M is comfortable with multi-country projects. The current A2M project portfolio reflects its long-time international coverage with health economic models being developed for Russia, Italy, Mexico, UK, France, Netherlands and Belgium.
Prior to setting up A2M, Dr. Nuijten was a partner with MEDTAP International. As a VP Business Development for Europe he established global Pricing and Reimbursement Consultancy Services for MEDTAP. Before MEDTAP, Dr. Nuijten was a Managing Director of the Quintiles office in the Netherlands.


Selected publications bridging health economics, pricing, market access and valuation

Fugel HJ, Nuijten M, Postma M. Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment.
N Biotechnol. 2016 Dec 25;33(6):860-867. doi: 10.1016/j.nbt.2016.09.00

Mark Nuijten. The Potential Impact of Current and Future Pharmaceutical Policy Changes on Cash Flows for Innovative Medicines. The Journal of Private Equity Vol. 18, No. 1 (WINTER 2014), pp. 34-45

Mark Nuijten, Marja Pronk. Financial Valuation Algorithm for the Assessment
of the Future Sales of a New, Innovative Medicinal Product. The Journal of Private Equity. Summer 2014, Vol. 17, No. 3: pp. 35-44. DOI: 10.3905/jpe

Mark Nuijten. Pitfalls in the Valuation of a Pharmaceutical Company. Journal of Private Equity. Fall 2013, Vol. 16, No. 4: pp. 57–66

Fugel HJ, Nuijten M, Faulkner E. The application of economics concepts to stratified medicine--use of health economics data to support market access for stratified medicine interventions. J Med Econ. 2014 May;17(5):305-11.

Walzer S, Nuijten M, Wiesner C, Kaier K, Johansson PO, Oertel S. Microeconomic surplus in health care: applied economic theory in health care in four European countries. Front Pharmacol. 2013 Feb 18;4:17.

Fugel HJ, Nuijten M, Postma M. Stratified medicine and reimbursement issues. Front Pharmacol. 2012;3:181.

Nuijten MJ, Dubois DJ. Cost-utility analysis: current methodological issues and future perspectives. Front Pharmacol 2011; 2 (1-5): 29.

Nuijten MJ, Van Gelder PH. Concise Equation That Captures the Essential Elements of One-Way Sensitivity Analyses in Health Economic Models. Med Decis Making 2011; 642-649.

Nuijten MJ, Mittendorf T, Persson U. Practical issues in handling data input and uncertainty in a budget impact analysis. Eur J Health Econ 2010; 231-241.

Mittendorf T, Briggs A, Bastida J L, Nuijten M & Persson U. Do Health Politicians Really Listen to Health Economists? - Observations from Europe. ISPOR Connections November/December 2009; 15(6): 15-16

Mauskopf JA, Sullivan SD, Caro J, Mullins CD, Nuijten M, J, Trueman P. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.Value Health. 2007 Sep-Oct;10(5):336-47.

Nuijten MJ. Pricing matrix model: dealing with uncertainty. Eur J Health Econ. 2007 Dec;8(4):333-7.

Nuijten MJC, Kosa J Pricing of Pharmaceuticals. Assessing the Pricing Potential by a Pricing Matrix Model. Eur J Health Econom 2004; 5:110-115.

Nuijten MJC. The Application of Free Market Theory to the Health Care Market. Eurohealth Winter 2003/2004; 9(4):13-17.

Nuijten MJC, Kosa J, Engelfriet P. Modeling the Cost-Effectiveness and Budgetary Impact for Subpopulations. European Journal of Health Economics 2003; 4:70-78.

Nuijten MJC and Rutten F. Combining a Budgetary Impact Analysis and a Cost-Effectiveness Analysis Using Decision Analytic Modelling Techniques. PharmacoEconomics 2002;20(12):855-67.

 
test
EBTNA Membership E-Newsletter
Copyright © 2017 EUROPEAN BIOTECHNOLOGY CONGRESS. All Rights Reserved.